Beam Therapeutics director granted 19,676 stock options
Beam Therapeutics Inc. director Graham K. Cooper reported receiving a grant of stock options to acquire 19,676 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Beam Therapeutics Inc. director Graham K. Cooper reported receiving a grant of stock options to acquire 19,676 shares of common stock. The options have an exercise price of $29.55 per share and expire on June 3, 2036.
The option vests in full on the earlier of the first anniversary of the grant date or immediately before next year’s annual stockholder meeting, provided he continues serving on the board through the vesting date. Following this grant, he holds 19,676 derivative securities directly.
Insider Trade Summary
Grant/Award: 19,676 shares
Grant/Award
1 txn
Insider
COOPER GRAHAM K
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 19,676 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 19,676 contracts (Direct)
Footnotes (1)
- F1. The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.
Key Figures
Options granted: 19,676 options
Exercise price: $29.55 per share
Underlying shares: 19,676 shares
+2 more
5 metrics
Options granted
19,676 options
Stock Option (Right to Buy) grant on June 3, 2026
Exercise price
$29.55 per share
Exercise price for Beam Therapeutics common stock
Underlying shares
19,676 shares
Underlying Beam Therapeutics common stock for the option
Post-grant derivative holdings
19,676 derivative securities
Total options held following the transaction
Expiration date
June 3, 2036
Option expiration for the reported grant
Key Terms
Stock Option (Right to Buy), exercise price, vesting, expiration date, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price of 29.5500 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The option vests in full on the earlier of the first anniversary of the date of grant"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-06-03T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
derivative securities financial
"he holds 19,676 derivative securities directly"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Beam Therapeutics (BEAM) director Graham K. Cooper report in this Form 4?
Graham K. Cooper reported receiving a grant of stock options for 19,676 shares of Beam Therapeutics common stock. These options are a compensation-related award, not an open-market stock purchase or sale, and are reflected as a derivative security holding.
How many Beam Therapeutics (BEAM) stock options were granted and at what price?
The filing shows a grant of 19,676 Beam Therapeutics stock options with an exercise price of $29.55 per share. This means he can buy that number of shares at $29.55, regardless of the market price, once the options vest.
When do Graham K. Cooper’s Beam Therapeutics (BEAM) options vest?
The options vest in full on the earlier of the first anniversary of the grant date or immediately before next year’s annual stockholder meeting. Vesting is conditioned on his continued service on Beam Therapeutics’ board through the applicable vesting date.
When do the reported Beam Therapeutics (BEAM) stock options expire?
The reported stock options expire on June 3, 2036. After that expiration date, Graham K. Cooper would no longer be able to exercise these options to purchase Beam Therapeutics common stock at the stated exercise price of $29.55 per share.
How many Beam Therapeutics (BEAM) derivative securities does Graham K. Cooper hold after this grant?
After this grant, the Form 4 shows Graham K. Cooper holding 19,676 derivative securities, all from this stock option award. These represent rights to purchase Beam Therapeutics common shares, subject to vesting and the option exercise price and expiration terms.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates